CAR T细胞治疗的现状与临床应用前景

嵌合抗原受体T细胞（CAR T）疗法是肿瘤过继免疫治疗的新手段。CAR T细胞疗法治疗B细胞急性淋巴细胞白血病（B ALL）的完全缓解率高达90％。然而，目前CAR T细胞疗法在血液肿瘤的治疗过程中尚存在脱靶效应、毒副作用、体内持续时间短与复发率高等问题。此外，在CAR T细胞治疗实体瘤方面的安全性和有效性虽已得到证实，但疗效还有待提高。本文对近年来CAR T细胞治疗的研究进展及该领域中亟需解决的问题作一分析与展望。

Current situation and clinical application prospect of CAR T cell therapy

Chimeric antigen receptor T cells （CAR T） therapy is a new method of tumor immunotherapy. The complete response rate of CAR T cell therapy for B cell acute lymphoblastic leukemia （B ALL） is as high as 90％. However， there are some problems of CAR T cell therapy in the treatment of blood tumor， such as off target activity， toxic side effect， short duration of the body and high recurrence rate. In addition， the safety and efficacy of CAR T cells in the treatment of solid tumors have been confirmed， but the efficacy remains to be improved. In this paper， the research progression of CAR T cell therapy in recent years and the urgent problems in this field are analyzed and prospected.